"Ozempic face" is the colloquial term for facial volume loss after rapid weight loss on GLP-1 therapy. It's real, it's predictable, and — with the right preparation — it's largely preventable. This is the practical guide.
Why it happens
Subcutaneous fat in the face, especially the buccal (cheek) and submandibular (under the jaw) areas, is highly responsive to overall body fat loss. Rapid drops in body fat draw down those depots quickly. The skin and underlying soft tissue have less time to remodel than they would in slower weight loss. The result is a hollower, more skeletal appearance — most visible in patients who were lower BMI to start.
Who is most affected
- Patients with BMI 27–32 who lose more than 15% body weight
- Patients over 45 (skin elasticity declines)
- Patients losing more than 1.5% body weight per week sustained
- Patients with low protein intake and no resistance training (combined sarcopenic loss)
What actually helps prevent it
- Slow titration — stretch out the time to maximum dose; aim for ~0.75% body weight per week, not 1.5%
- Protein floor — 1.6 g/kg body weight as the daily minimum
- Resistance training — facial appearance correlates with overall body composition; preserving lean mass helps the face stay full
- Hydration — chronic dehydration accentuates facial volume loss
- Sleep — short sleep accelerates skin aging and impairs lean-mass retention
Cosmetic interventions, if needed
For patients who experience significant facial volume loss despite the above, dermal fillers (hyaluronic acid, polylactic acid, calcium hydroxylapatite) and biostimulators are the standard interventions. These should be performed by a board-certified dermatologist or facial plastic surgeon. We don't recommend pursuing cosmetic intervention until weight has stabilized — typically 6 months after reaching goal.
Bottom line
Ozempic face is the predictable result of rapid weight loss in patients who were not at very high BMI to start, especially without protein and resistance-training support. The mitigation protocol is the same as the muscle-preservation protocol. The combined intervention is one of the highest-leverage things you can do on GLP-1 therapy.
NexLife scored highest on our rubric (94/100) for rigorous safety oversight. Flat-rate pricing across full titration, labs included, MD/DO oversight, both 503A and 503B pharmacy partners.
This article was authored by Eduard Cristea and clinically reviewed by Dr. A. Goher, MD. Health Technology Researcher & Publisher. See our methodology and affiliate disclosure.